Fennec Pharmaceuticals INC Form 4 insider transactions

Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common share acquisitions on April 17 and 18, 2024.

Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common shares acquired through option exercises under a 10b5-1 plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, executed option exercises and subsequent share disposals under a pre-arranged 10b5-1 trading plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, reports transactions involving the exercise of options and disposal of common shares under a pre-arranged 10b5-1 trading plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, reports transactions involving common shares and options, including acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Director Chris A. Rallis of Fennec Pharmaceuticals reports the sale of 800 common shares and the exercise of options for 1,389 shares on April 15, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov sold a total of 88,583 common shares between April 4th and April 5th, 2024, under a pre-arranged 10b5-1 trading plan.

Fennec Pharmaceuticals CEO Rosty Raykov sold a total of 40,584 common shares on April 3, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 12,500 common shares on April 1, 2024, due to the release of restrictions from shares awarded on March 31, 2023.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the release of restriction from 29,167 common shares awarded on March 31, 2023, resulting in a total beneficial ownership of 316,638 shares.

Director Chris A. Rallis of Fennec Pharmaceuticals reports the sale and acquisition of common shares, including transactions related to option exercises and a pre-arranged 10b5-1 trading plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, sold 13,975 common shares at a price of $10.9013 per share on March 26, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, sold 13,975 common shares at $10.9975 per share on March 25, 2024, under a pre-arranged 10b5-1 trading plan.